(Q38537424)

3 September 2017

title

Chemotherapy of ovarian cancer directed by the human tumor stem cell assay (English)

1 reference

3 September 2017

1 reference

neoplastic stem cells

1 reference

1

D S Alberts

1 reference

3 September 2017

3

S E Salmon

1 reference

3 September 2017

Frank L. Meyskens, Jr.

series ordinal

7

object named as

F L Meyskens

1 reference

3 September 2017

4

E A Surwit

1 reference

3 September 2017

H S Chen

2

1 reference

3 September 2017

L Young

series ordinal

5

1 reference

3 September 2017

T E Moon

series ordinal

6

1 reference

3 September 2017

publication date

1 January 1981

1 reference

Cancer Chemotherapy and Pharmacology

3 September 2017

published in

1 reference

3 September 2017

volume

6

1 reference

3 September 2017

issue

3

1 reference

3 September 2017

page(s)

279-285

1 reference

Management of ovarian carcinoma. Current concepts and future prospects (first of two parts)

3 September 2017

cites work

1 reference

12 December 2020

The CHAD and HAD regimens in advanced ovarian cancer: combination chemotherapy including cyclophosphamide, hexamethylmelamine, adriamycin, and cis-dichlorodiammineplatinum(II)

1 reference

12 December 2020

cis-Dichlorodiammineplatinum(II) for the treatment of advanced ovarian cancer

1 reference

12 December 2020

Quantitative association between the in vitro human tumor stem cell assay and clinical response to cancer chemotherapy

1 reference

12 December 2020

Preparation of permanent slides of intact soft-agar colony cultures of hematopoietic and tumor stem cells

1 reference

12 December 2020

Treatment of Ovarian Carcinoma: Possibilities for Progress

1 reference

12 December 2020

Chemotherapy for stage III-IV epithelial ovarian cancer with cis-dichlorodiammineplatinum(II), adriamycin, and cyclophosphamide: a preliminary report

1 reference

12 December 2020

Chemotherapy of ovarian cancer: past and present

1 reference

12 December 2020

Hormone receptors: their role in predicting prognosis and response to endocrine therapy

1 reference

12 December 2020

Uptake of melphalan by human ovarian carcinoma cells and its relationship to the amino acid content of ascitic fluid

1 reference

12 December 2020

Adriamycin therapy for advanced ovarian carcinoma recurrent after chemotherapy

1 reference

12 December 2020

In-vitro clonogenic assay for predicting response of ovarian cancer to chemotherapy

1 reference

12 December 2020

Adriamycin in ovarian cancer patients resistant to cyclophosphamide

1 reference

12 December 2020

Amino acid-conferred protection against melphalan--characterization of melphalan transport and correlation of uptake with cytotoxicity in cultured L1210 murine leukemia cells

1 reference

12 December 2020

Second trial drugs in ovarian cancer

1 reference

12 December 2020

Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs

1 reference

12 December 2020

Primary Bioassay of Human Tumor Stem Cells

1 reference

12 December 2020

Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy

1 reference

12 December 2020

Direct cloning of human ovarian carcinoma cells in agar

1 reference

12 December 2020

Phase II trial of vindesine in the treatment of lymphomas, breast cancer, and other solid tumors

1 reference

12 December 2020

Effect of pH on the bleomycin-induced DNA single-strand scission in L1210 cells and the relation to cell survival

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF00256981

0 references

1 reference